Clarinex

Clarinex. It is a second-generation antihistamine medication primarily used for the symptomatic relief of allergic rhinitis and chronic idiopathic urticaria. The drug is the active metabolite of loratadine, which is marketed under the brand name Claritin. Developed by the pharmaceutical company Schering-Plough, it received approval from the U.S. Food and Drug Administration in the early 2000s and is available by prescription in several formulations.

Medical uses

It is indicated for the relief of symptoms associated with seasonal allergic rhinitis, such as sneezing, rhinorrhea, and ocular pruritus, in patients aged two years and older. It is also approved for the treatment of perennial allergic rhinitis and the reduction of pruritus and lesion count in patients with chronic idiopathic urticaria. Clinical studies, including those published in the Journal of Allergy and Clinical Immunology, have demonstrated its efficacy compared to placebo and other agents like fexofenadine. Its use is generally not recommended for the treatment of acute bronchospasm or status asthmatics.

Adverse effects

In clinical trials, adverse events were reported at a rate similar to placebo. The most commonly observed effects include pharyngitis, dry mouth, myalgia, fatigue, somnolence, and dysmenorrhea. Serious adverse effects are rare but can include hypersensitivity reactions such as anaphylaxis and angioedema. The European Medicines Agency and the U.S. Food and Drug Administration monitor post-marketing safety data, which has included reports of hepatitis and palpitations. It has a favorable cardiac safety profile, with no significant QT interval prolongation observed, unlike some first-generation antihistamines such as terfenadine.

Pharmacology

As a selective peripheral histamine H1 receptor antagonist, it inhibits the release of histamine from mast cells and basophils. Its chemical structure is a tricyclic derivative, closely related to loratadine but with a higher affinity for the H1 receptor. The drug undergoes extensive hepatic metabolism primarily via CYP3A4 and CYP2D6 enzymes to form an active metabolite, 3-hydroxydesloratadine. Pharmacokinetic studies show a mean elimination half-life of approximately 27 hours, supporting its once-daily dosing regimen.

History

The development was a direct result of research into the metabolic pathways of loratadine, which was discovered by scientists at Schering-Plough. Following the expiration of the patent for Claritin, the company sought to introduce a successor product. New Drug Application submissions were made to the U.S. Food and Drug Administration, leading to approval for use in the United States in 2002. Subsequent approvals were granted by regulatory bodies worldwide, including the European Medicines Agency and Health Canada.

Society and culture

It has been marketed under various brand names globally, including Aerius in Canada and Europe, and Neoclarityn in the United Kingdom. The introduction of the drug was part of a larger commercial strategy in the competitive antihistamine market, competing directly with products like Zyrtec from Pfizer and Allegra from Sanofi. Its patent protection and subsequent litigation have been subjects of discussion within the pharmaceutical industry. The medication is available as a prescription product in most countries, though some regions have since made it available over-the-counter.

Category:Antihistamines Category:Schering-Plough Category:Drugs developed in the United States